List of Nexiclon Xr drug patents

Nexiclon Xr is owned by Athena.

Nexiclon Xr contains Clonidine.

Nexiclon Xr has a total of 2 drug patents out of which 0 drug patents have expired.

Nexiclon Xr was authorised for market use on 03 December, 2009.

Nexiclon Xr is available in tablet, extended release;oral dosage forms.

The generics of Nexiclon Xr are possible to be released after 08 September, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8337890 ATHENA Modified release formulations containing drug-ion exchange resin complexes
Apr, 2027

(4 years from now)

US8623409 ATHENA Clonidine formulation
Sep, 2031

(8 years from now)

Drugs and Companies using CLONIDINE ingredient

Market Authorisation Date: 03 December, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic